Stockscreener 앱 받기
0.0001
33.64%
-0.0602
전일 마감가:
$0.0603
열려 있는:
$0.0001
하루 거래량:
161
Relative Volume:
시가총액:
$N/A
수익:
-
순이익/손실:
$-18.29M
주가수익비율:
-0.000007
EPS:
-15.1779
순현금흐름:
$-10.77M
1주 성능:
-33.64%
1개월 성능:
-57.01%
6개월 성능:
-93.93%
1년 성능:
-85.81%
1일 변동 폭
$0.0001
$0.0001
1주일 범위
$0.0001
$0.0001
52주 변동 폭
$0.0001
$0.0001
팩스메디카 Stock (PXMD) Company Profile
PXMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.0001 | 0 | 0 | -18.29M | -10.77M | -15.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
팩스메디카 주식(PXMD)의 최신 뉴스
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
PaxMedica announces board resignations amid transition By Investing.com - Investing.com Canada
PaxMedica announces board resignations amid transition - Investing.com Australia
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica, Inc. Announces Board Changes -February 06, 2025 at 04:05 pm EST - Marketscreener.com
Paxmedica, Inc. Announces Resignation of Stephen D. Sheldon as Chief Financial Officer - Marketscreener.com
PaxMedica CFO and COO Stephen D. Sheldon Resigns, Zachary Rome Steps Down from BoardOn January 31, 2025, PaxMedica, Inc. (NASDAQ:PXMD) saw significant changes in its executive leadership and board composition. Stephen D. Sheldon, the chie - Defense World
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment - Financial Content
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - Yahoo Finance
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Yahoo Finance
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - GlobeNewswire
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
Paxmedica Inc (PXMD) QuotePress Release - The Globe and Mail
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - StreetInsider
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
What's Going On With PaxMedica Stock Today? - Benzinga
Why Is PaxMedica (PXMD) Stock Up 95% Today? - InvestorPlace
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - GlobeNewswire
PaxMedica (NASDAQ: PXMD) to jump 1,700% todaypurely nominal and technical - Dhaka Tribune
PaxMedica Announces 1-for-17 Reverse Stock Split - GlobeNewswire
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication - GlobeNewswire
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - GlobeNewswire
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC - GlobeNewswire
PaxMedica Comments on Common Stock Volatility - GlobeNewswire
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month - Yahoo Finance
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More By Benzinga - Investing.com UK
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results - Yahoo Finance
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch - Penny Stocks
Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
PaxMedica Releases 2022 Shareholder Letter - Yahoo Finance
팩스메디카 (PXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
1.98%
자본화:
|
볼륨(24시간):